Source:http://linkedlifedata.com/resource/umls/id/C1327944
NCI: IDEC-152 was developed to decrease the body's response to allergens, thereby affecting diseases related to asthma and allergic disorders. This chimeric monoclonal antibody binds to the CD23 receptor, by which IDEC-152 may favorably influence asthma through its selective regulation of IgE production and its inhibition of other inflammatory pathways.